Phase I/II study of the WEE1 inhibitor adavosertib (AZD1775) in combination with carboplatin in children with advanced malignancies: Arm C of the AcSé-ESMART trial.

Susanne Andrea Gatz Anne C Harttrampf Caroline Brard Francisco J Bautista Sirvent Anne Isabelle Bertozzi Samuel D Abbou Jonathan Rubino Windy Rondof Marc Deloger Marc Rübsam Lynley V Marshall Daniel Hübschmann Souad Nebchi Isabelle Aerts Estelle Thebaud Emilie De Carli Anne-Sophie Defachelles Xavier Paoletti Robert Godin Kowser Miah Peter G S Mortimer Gilles Vassal Didier Frappaz

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)

Adavosertib-carboplatin combination exhibited significant hematologic toxicity. Activity signals and identified potential biomarkers suggest further studies with less hematotoxic DNA damaging therapy in molecularly enriched pediatric cancers.

Keyphrases

phase iii
phase ii study
acute coronary syndrome
young adults
clinical trial
study protocol
cell free
circulating tumor
open label
oxidative stress
phase ii
randomized controlled trial
squamous cell carcinoma
bone marrow
radiation therapy
cell therapy
nucleic acid